Compare Adaptive Biotechnologies Corp (ADPT) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X Lithium & Battery Tech ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.13 (market cap $4.04B), while Global X Lithium & Battery Tech ETF trades at $75.31. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | LIT | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $91.62 |
52-Week Low | $12.30 | $44.96 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
LIT trades at $75.60, up 1.15% with a bullish technical signal from moving averages and ADX, though RSI indicates overbought conditions. Recent news highlights strong EV sales growth and lithium demand catalysts, but key financial ratios are unavailable. The stock shows tight support at $74 and resistance at $75.
Outlook is positive due to EV and energy storage momentum, but risks include overbought technicals and reliance on lithium market cycles. Investment opportunity hinges on sustained demand growth, while volatility from commodity prices and competition poses challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
